Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer

Cole MP: Suppression of ovarian function in primary breast cancer.In Forrest APM, Kunkler PB (eds): Prognostic Factors in Breast Cancer. E and S Livingston, Edinburgh, 1968, pp 146–156

Tormey DC: Combined chemotherapy and surgery in breast cancer: a review. Cancer 36:881–892, 1975

Fisher B, Ravdin RG, Ausman RK, Slack NH, Moore GE, Noer RJ, et al.: Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigations. Ann Surg 168:337–356, 1968

Nissen-Meyer R, Kjellgren K, Malmio K, Månsson B, Norin T: Surgical adjuvant chemotherapy. Results with one short course with cyclophospha mide after mastectomy for breast cancer. Cancer 41:2088–2098, 1978

Schabel FM Jr: Rationale for adjuvant chemotherapy. Cancer 39:2875–2882, 1977

Skipper HE, Schabel FM Jr: Tumor stem cell hetero-geneity: implications with respect to classification of cancers by chemotherapeutic effect. Cancer Treat Rep 68:43–61, 1984

Martin DS, Fugman RA, Stolfi RL, Hayworth PE: Solid tumor animal model therapeutically predictive for human breast cancer. Cancer Chemother Rep 5:89–109, 1975

Fisher B, Slack N, Katrych D, Wolmark N: Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140:528–534, 1975

Valagussa P, Bonadonna G, Veronesi U: Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer 41:1170–1178, 1978

Bonadonna G: Citation Classic. Commentary on N Engl J Med 294:405–10. Current Contents/Clinical Practice, 1985 (in press)

Canellos GP, De Vita CT, Lennard Gold G, Chabner BA, Schein PS, Young RC: Cyclical combination chemotherapy for advanced breast carcinoma. Br Med J 1:218–220, 1974

Canellos GP, Pocock SJ, Taylor SG III, Sears ME, Klaasen DJ, Band PR: Combination chemotherapy for metastatic breast cancer. Prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer 38:1882–1886, 1976

Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, Redmond C, Zelen M, Band P, Katrych DL, Wolmark N, Fisher ER, et al.: L-phenylalanine mustard (L-PAM) in the management of primary breast cancer: a report of early findings. N Engl J Med 292:117–122, 1975

Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405–410, 1976

Norton L, Simon R: Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61:1307–1317, 1977

Bonadonna G, Bignami P, Buzzoni R, Moliterni A, Valagussa P, Veronesi U: New adjuvant trials for resectable breast cancer at the Istituto Nazionale Tumori of Milan. Recent Results Cancer Res 91:210–213, 1984

Bonadonna G, Rossi A, Valagussa P, Banfi A, Veronesi U: The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance. Cancer 39:2904–2915, 1977

Tancini G, Bajetta E, Marchini S, Valagussa P, Bonadonna G, Veronesi U: Preliminary 3-year results of 12 versus 6 cycles of surgical adjuvant CMF in premenopausal breast cancer. Cancer Clin Trials 2:285–292, 1979

Rossi A, Bonadonna G, Valagussa P, Veronesi U: Multimodal treatment in operable breast cancer: five-year results of the CMF programme. Br Med J 282:1427–1431, 1981

Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10–15, 1981

Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U: Adjuvant CMF in breast cancer. Comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1:2–10, 1983

Bonadonna G, Valagussa P: Adjuvant systemic therapy for resectable breast cancer. J Clin Oncol 3:259–275, 1985

Bonadonna G, Rossi A, Tancini G, Brambilla C, Valagussa P: Adjuvant chemotherapy trials in resectable breast cancer with positive axillary nodes. The experience of the Milan Cancer Institute.In Jones SE, Salmon SE (eds): Adjuvant Therapy of Cancer IV. Grune & Stratton, New York, 1984, pp 195–208

Bonadonna G, Valagussa P, De Palo G: The results of adjuvant chemotherapy are predominantly caused by the hormonal changes such therapy induces. Opposed.In Van Scoy-Mosher MB (ed): Medical Oncology. Controversies in Cancer Treatment. GK Hall & Co., Boston, 1981, pp 100–109

Brambilla C, De Lena M, Rossi A, Valagussa P, Bonadonna G: Response and survival in advanced breast cancer after two non-cross resistant combinations. Br Med J 1:801–804, 1976

Rossi A, Brambilla C, Valagussa P, Bonadonna G: Adjuvant programs for postmenopausal women with node positive breast cancer: preliminary analysis of 5-year results. Recent Res Cancer Res 96:178–183, 1984

Jones SE, Salmon SE (eds): Adjuvant Therapy of Cancer IV. Grune & Stratton, New York, 1984

Glass A, Wieand HS, Fisher B, Redmond C, Lerner H, Wolter J, Shibata H, Plotkin D, Foster R, Margolese R, Wolmark N, et al.: Acute toxicity during adjuvant chemotherapy for breast cancer: The National Surgical Adjuvant Breast and Bowel Project (NSABP) experience from 1717 patients receiving single and multiple agents. Cancer Treat Rep 65:363–376, 1981

Valagussa P, Moliterni A, Buzzoni R, Bignami P, Bonadonna G, Veronesi U: Acute toxicity of intravenous chemotherapy in adjuvant breast cancer trials. Proc AACR 24:141, 1983

Knobf MK, Mullen JC, Xistris D, Moritz DA: Weight gain in women with breast cancer receiving adjuvant chemotherapy. Oncol Nurs Forum 10:28–33, 1983

Pourquier H: The results of adjuvant chemotherapy are predominantly caused by the hormonal changes such therapy induces. In favor.In Van Scoy-Mosher MB (ed): Medical Oncology. Controversies in Cancer Treatment. GK Hall & Co., Boston, 1981, pp 83–99

Howell A, George WD, Crowther D, Rubens RD, Bulbrook RD, Bush H, Howat JMT, Sellwood RA, Hayward JL, Fentiman IS, Chaudary M: Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Lancer ii:307–311, 1983

Shalet SM: Effects of cancer chemotherapy on gonadal function of patients. Cancer Treat Rev 7:141–152, 1980

Rose DP, Davis TE: Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet ii:1174–1176, 1977

Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS: Progesterone receptor as a prognostic factor in Stage II breast cancer. N Engl J Med 309:1343–1347, 1983

Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J, Escher G, Lippman M, Savlov E, Wittliff J, Fisher ER, Plotkin D, Bowman D, Wolter J, Bornstein R, Desser R, Frelick R, et al.: Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1:227–241, 1983

Blamey RW, Elston CW: Trials of adjuvant chemotherapy in breast cancer. Lancet i:920, 1979

Langlands OA, Tiver KW: Letter to the Editor. Int J Radiat Oncol Biol Phys 10:943, 1984

Valagussa P, Rossi A, Tancini G, Bonadonna G: Is there any effective salvage treatment for relapsing operable breast cancer with N+? Proc ASCO, 1985

Fisher RI, De Vita VT, Hubbard SM, Simon R, Young RC: Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 90:761–763, 1979

Bonadonna G, Valagussa P: Comment on ‘The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival’. Cancer Treat Rep 67:527–529, 1983

Bonadonna G: Chemotherapy strategies to improve the control of Hodgkin's disease. The Richard and Hinda Rosenthal Foundation Memorial Lecture. Cancer Res 42:4309–4320, 1982

Redding WH, Monaghan P, Imrie SF, Ormerod MG, Gazet JL, Coombes RC, Clink HM, Dearnaley DP, Sloane JP, Powles TJ, Neville AM: Detection of micrometastases in patients with primary breast cancer. Lancer ii:1271–1274, 1983